Short Term Effect of Intranasal Administration of Hexarelin — A Synthetic Growth Hormone-Releasing Peptide. Preliminary Communication
- 1 January 1995
- journal article
- clinical trial
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 8 (1) , 43-46
- https://doi.org/10.1515/jpem.1995.8.1.43
Abstract
Twice or three times daily intranasal administration of the hexapeptide hexarelin for 7 days to children with short stature and normal growth hormone (GH) secretion evoked a significant rise in serum levels of insulin-like growth factor-1 (IGF-1) and alkaline phosphatase. There was also a significant, within normal limits, rise of thyroid stimulating hormone (TSH) without evidence of thyroxine suppression.Keywords
This publication has 5 references indexed in Scilit:
- Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)Clinical Endocrinology, 1994
- Growth hormone-releasing activity of hexarelin in humansEuropean Journal of Clinical Pharmacology, 1994
- Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in manJournal of Clinical Endocrinology & Metabolism, 1994
- Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescentsActa Endocrinologica, 1993
- Biochemical and hormonal changes induced by one week of administration of rIGF‐I to patients with Laron type dwarfismClinical Endocrinology, 1991